
TY  - JOUR
TI  - Posters
JO  - Bipolar Disorders
JA  - Bipolar Disord
VL  - 20
IS  - S1
SN  - 1398-5647
UR  - https://doi.org/10.1111/bdi.12619
DO  - doi:10.1111/bdi.12619
SP  - 63
EP  - 141
PY  - 2018
ER  - 

TY  - JOUR
AU  - Kutney, Katherine
AU  - Konczal, Laura
AU  - Kaminski, Beth
AU  - Uli, Naveen
TI  - Challenges in the diagnosis and management of disorders of sex development
JO  - Birth Defects Research Part C: Embryo Today: Reviews
JA  - Birth Defect Res C
VL  - 108
IS  - 4
SN  - 1542-975X
UR  - https://doi.org/10.1002/bdrc.21147
DO  - doi:10.1002/bdrc.21147
SP  - 293
EP  - 308
KW  - disorders of sex development
KW  - SRY
KW  - NR5A1
KW  - gonadal dysgenesis
KW  - adrenal hyperplasia
PY  - 2016
AB  - Disorders of sex development (DSD) represent a spectrum of uncommon but very complex disorders with medical, psychosexual, and family implications for those affected by them. The diagnosis and management of these disorders requires a coordinated team of multiple specialists. Following an international conference in Chicago in 2005, a consensus statement was created and presented, which has resulted in a new paradigm in the nomenclature, classification, and management of DSDs. Since that time, many improvements have been forthcoming, most notably in the area of molecular genetic technologies. These developments have advanced our understanding of the specific etiologies underlying many of these conditions. In this article, we present an overview of the physiology of sex development, a few clinical vignettes highlighting specific pathologic conditions, discussions regarding the evaluation and management of these disorders, and some thoughts on future directions in this field. Birth Defects Research (Part C) 108:293?308, 2016. ? 2016 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
TI  - Vascular Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_24.x
DO  - doi:10.1111/j.1445-2197.2010.05298_24.x
SP  - A98
EP  - A101
PY  - 2010
ER  - 

TY  - JOUR
TI  - Colorectal Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_5.x
DO  - doi:10.1111/j.1445-2197.2010.05298_5.x
SP  - A15
EP  - A24
PY  - 2010
ER  - 

TY  - JOUR
TI  - E-Poster Presentations (Oral) | APDW 2019
JO  - Journal of Gastroenterology and Hepatology
JA  - Journal of Gastroenterology and Hepatology
VL  - 34
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.14879
DO  - doi:10.1111/jgh.14879
SP  - 72
EP  - 582
PY  - 2019
ER  - 

TY  - JOUR
TI  - Paediatric Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_13.x
DO  - doi:10.1111/j.1445-2197.2010.05298_13.x
SP  - A53
EP  - A55
PY  - 2010
ER  - 

TY  - JOUR
TI  - Pain Medicine Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_14.x
DO  - doi:10.1111/j.1445-2197.2010.05298_14.x
SP  - A56
EP  - A57
PY  - 2010
ER  - 

TY  - JOUR
TI  - Surgical Oncology Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_20.x
DO  - doi:10.1111/j.1445-2197.2010.05298_20.x
SP  - A87
EP  - A89
PY  - 2010
ER  - 

TY  - JOUR
TI  - Endocrine Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_6.x
DO  - doi:10.1111/j.1445-2197.2010.05298_6.x
SP  - A25
EP  - A29
PY  - 2010
ER  - 

TY  - JOUR
TI  - Hapatopancreaticobiliary and Upper GI Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_9.x
DO  - doi:10.1111/j.1445-2197.2010.05298_9.x
SP  - A42
EP  - A48
PY  - 2010
ER  - 

TY  - JOUR
TI  - Workshops
JO  - European Journal of Clinical Investigation
VL  - 41
IS  - s1
SN  - 0014-2972
UR  - https://doi.org/10.1111/j.1365-2362.2011.02508.x
DO  - doi:10.1111/j.1365-2362.2011.02508.x
SP  - 23
EP  - 86
PY  - 2011
ER  - 

TY  - JOUR
AU  - Säemann, M.
AU  - Hörl, W. H.
TI  - Urinary tract infection in renal transplant recipients
JO  - European Journal of Clinical Investigation
VL  - 38
IS  - s2
SN  - 0014-2972
UR  - https://doi.org/10.1111/j.1365-2362.2008.02014.x
DO  - doi:10.1111/j.1365-2362.2008.02014.x
SP  - 58
EP  - 65
KW  - Immunosuppression
KW  - renal transplantation
KW  - urinary tract infection
KW  - uropathogens
PY  - 2008
AB  - ABSTRACT Urinary tract infection (UTI) is common in renal transplant recipients. Frequency of UTIs depend on many factors such as age, female gender, kidney function, co-morbidity, type and amount of immunosuppression, urological instrumentation and/or the follow-up period (short term or long term) after kidney transplantation. UTI may worsen graft and patient survival. A significant proportion of renal transplant recipients with UTIs may develop acute pyelonephritis (APN), which is an independent risk factor for deterioration of graft function. Renal transplant recipients with UTIs are often clinically asymptomatic as a consequence of immunosuppression. UTI, however, may progress to APN (particularly in the early post-transplant period), bacteraemia and the full blown picture of urosepsis. Strategies for long term prophylaxis and antimicrobial treatment of UTI in renal transplant recipients are discussed.
ER  - 

TY  - JOUR
TI  - Military Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_12.x
DO  - doi:10.1111/j.1445-2197.2010.05298_12.x
SP  - A51
EP  - A52
PY  - 2010
ER  - 

TY  - JOUR
TI  - Rural Surgery Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_16.x
DO  - doi:10.1111/j.1445-2197.2010.05298_16.x
SP  - A76
EP  - A77
PY  - 2010
ER  - 

TY  - JOUR
TI  - ANZSCMFS (Craniomaxillofacial Surgery) Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_2.x
DO  - doi:10.1111/j.1445-2197.2010.05298_2.x
SP  - A5
EP  - A5
PY  - 2010
ER  - 

TY  - JOUR
TI  - Burn Program Abstracts
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_1.x
DO  - doi:10.1111/j.1445-2197.2010.05298_1.x
SP  - A1
EP  - A4
PY  - 2010
ER  - 

TY  - JOUR
TI  - Senior Surgeons Program Abstract
JO  - ANZ Journal of Surgery
VL  - 80
IS  - s1
SN  - 1445-1433
UR  - https://doi.org/10.1111/j.1445-2197.2010.05298_17.x
DO  - doi:10.1111/j.1445-2197.2010.05298_17.x
SP  - A78
EP  - A78
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Neuropathology and Applied Neurobiology
JA  - Neuropathol Appl Neurobiol
VL  - 41
IS  - S1
SN  - 0305-1846
UR  - https://doi.org/10.1111/nan.12224
DO  - doi:10.1111/nan.12224
SP  - 30
EP  - 58
PY  - 2015
ER  - 

TY  - JOUR
AU  - Antoine, Thessicar E.
AU  - Park, Paul J.
AU  - Shukla, Deepak
TI  - Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
JO  - Reviews in Medical Virology
JA  - Rev. Med. Virol.
VL  - 23
IS  - 3
SN  - 1052-9276
UR  - https://doi.org/10.1002/rmv.1740
DO  - doi:10.1002/rmv.1740
SP  - 194
EP  - 208
PY  - 2013
AB  - SUMMARY Herpes simplex virus type-1 (HSV-1) is among the most common human pathogens worldwide. Its entry into host cells is an intricate process that relies heavily on the ability of the viral glycoproteins to bind host cellular proteins and to efficiently mediate fusion of the virus envelope with the cell membrane. Acquisition of HSV-1 results in a lifelong latent infection. Because of the cycles of reactivation from a latent state, much emphasis has been placed on the management of infection through the use of DNA synthesis inhibitors. However, new methods are needed to provide more effective treatment at earlier phases of the viral infection and to prevent the development of drug resistance by the virus. This review outlines the infection process and the common therapeutics currently used against the fundamental stages of HSV-1 replication and fusion. The remainder of this article will focus on a new approach for HSV-1 infection control and management, the concept of glycoprotein-receptor targeting. Copyright ? 2013 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - THSNA 2018 Summit Abstract Proceedings
JO  - American Journal of Hematology
JA  - Am J Hematol
VL  - 93
IS  - 9
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.25268
DO  - doi:10.1002/ajh.25268
SP  - E253
EP  - E328
PY  - 2018
ER  - 
